热门资讯> 正文
瑞银上调估值，LifeStance Health飙升
2025-05-28 02:42
- Shares of LifeStance Health (NASDAQ:LFST) traded higher on Tuesday after UBS upgraded the behavioral health services firm to Buy from Neutral, citing a mismatch between the company’s performance and its valuation.
- The upgrade comes after LifeStance’s (NASDAQ:LFST) ~17% drop this year. “Despite the sell-off, which dates back to March, our view is that LFST’s long-term growth profile remains intact,” Bloomberg News reported, quoting UBS analysts led by Kevin Caliendo.
- The firm issued an $8.50 per share target on LFST, arguing that the stock trades at an attractive entry point for investors.
- Wall Street has remained bullish on LifeStance (NASDAQ:LFST) stock, with an average rating of Buy from analysts in line with Seeking Alpha Author ratings. However, Seeking Alpha's Quant System, which consistently beats the market, rated LFST as a Hold.
More on LifeStance Health Group
- LifeStance Health Group, Inc. (LFST) Q1 2025 Earnings Call Transcript
- LifeStance Health Group: Solid Execution Drives Growth And Margin Expansion
- LifeStance Health Group, Inc. 2024 Q4 - Results - Earnings Call Presentation
- LifeStance Health wins bullish view at KeyBanc on growth prospects
- LifeStance Health appoints Bourdon as CEO
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
